Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Inclusion Criteria: * Documented history of pulmonary sarcoidosis for at least 6 months, supported by the following evidence: documented histologically proven diagnosis of sarcoidosis by tissue biopsy and documented evidence of parenchymal lung involvement by historical radiological evidence * Evidence of symptomatic pulmonary sarcoidosis, as demonstrated by the following criteria: Modified Medical Research Council (MRC) dyspnea scale grade of at least 1 and KSQ-Lung score ≤70 * Patients must be receiving treatment with OCS of ≥ 3 months at Day 1 with a starting dose between ≥ 7.5 and ≤ 25 mg/day ≥ 4 weeks prior to Day 1. * Body weight ≥ 40 kg and \< 160 kg Exclusion Criteria: * Treatment with \> 1 immunosuppressant therapy * Treatment with biological immunomodulators, such as tumor necrosis factor-alpha (TNF-α) inhibitors or antifibrotics or interleukin inhibitors * Likelihood of significant pulmonary fibrosis as shown by any 1 or more of the following: High resolution CT fibrosis \> 20% within the last 12 months; FVC percent predicted (FVCPP) \< 50% and KSQ-Lung score \< 30 * In the opinion of the investigator, clinically significant pulmonary hypertension * Patients with active cardiac, neuro, or renal sarcoidosis requiring organ-specific therapy in the past 2 years * Patients with cutaneous or ocular sarcoidosis, which in the opinion of the Investigator, are at risk for exacerbation, necessitating OCS rescue or other systemic therapy * History of Addisonian symptoms that precluded previous OCS taper attempts * Is an active, heavy smoker of tobacco/nicotine-containing products * History of anti-synthetase syndrome or Jo-1 positive at Screening * Patients with active tuberculosis or those currently undergoing treatment for tuberculosis